Target detail

ALG13

ALG13 UDP-N-acetylglucosaminyltransferase subunit

Data: Live structured evidence (Supabase)

Marker index metadata

Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).

Display name: ALG13 UDP-N-acetylglucosaminyltransferase subunit

Aliases: ALG13, ALG13 UDP-N-acetylglucosaminyltransferase subunit

Type / organism: protein_coding · Homo sapiens

Source: opentargets · ENSG00000101901

Index freshness: last_synced_at 2026-05-15T20:13:22.177+00:00 · updated 2026-05-15T20:13:22.785687+00:00

Disease hub (glioblastoma)Guided · ALG13

Limitations & build flags

Read-only structured navigator
No clinical outcome benefit inferred
Trial presence does not imply success
Drug identity may require normalization
Terminated/withdrawn trials must remain visible

Target index (foundation)

This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.

Glioblastoma disease hub·Guided lookup

Live structured evidence · sources

Connectors represented in loaded rows for ALG13. Empty groups mean no matching rows — not a claim about biology or clinical use.

Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).

Open Targets · disease–target evidence

Rows from disease_target_evidence for this symbol.

No matching live evidence found

Ingest Open Targets disease–target rows for this symbol to populate this section.

ChEMBL · linked drugs (drug_targets)

Drug records tied via drug_targets — mechanistic linkage only.

No linked drug rows

When drug_targets and drugs rows exist for this symbol, they are listed here.

repoDB-style · approved-elsewhere discussion candidates

disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.

No matching rows

Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.

ClinicalTrials.gov · trial-matched options

Mirror rows whose text fields mention this symbol — registry context only.

No matching live evidence found

Populate clinical_trials via the registry enrichment flow; this panel matches the symbol token in titles, conditions, or interventions.

CANTI signal builder · target-linked research signals

Repurposing signal rows for drugs linked to this target via drug_targets.

No research signals for linked drugs

Run the deterministic signal builder after drug_targets and source rows are present.

Caution / negative-evidence rows

Structured rows with negative evidence_direction on disease–drug or signal tables.

No negative-direction rows

When structured evidence includes explicit negative direction fields, they surface here for oncology review.

Missing evidence · row counts by source string

This symbol is listed in the canti target index — drug_targets and disease_target_evidence may still be empty until connector jobs populate those tables.

No ClinicalTrials.gov mirror rows mention this symbol in titles, conditions, or interventions (within the loaded window).

No source strings on loaded rows yet.

Summary row (aggregated list)

Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.

Disease contexts

Linked drugs

Linked in dataset

Research signals

Evidence badges (illustrative)

Doctor-discussion candidate and related tags are descriptive only.

Appears in source landscapeLinked in datasetRequires oncology review

Linked research signals (list read)

Signals list: Live structured evidence (Supabase)

No matching live evidence found

When repurposing_signal rows reference this marker via linked drugs, summaries appear here.